Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
New draft guidance could see the agency getting ever stricter.
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Interius, one of the most advanced players, will cost $350m.
Posters and mini-orals include another VEGF bispecific.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
